Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer

Author： Airoldi M.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.70, Iss.3, 2001-12, pp. : 185-195

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

By Airoldi Mario   Cattel Luigi   Pedani Fulvia   Marchionatti Sara   Tagini Valentina   Bumma Cesare   Recalenda Valeria  

Acta Oncologica, Vol. 42, Iss. 3, 2003-01 ,pp. : 186-194

Informa Healthcare

Access to resources Recommend Favorite

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite

Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study

By Bonneterre J.   Campone M.   Koralewski P.   Blasinska-Morawiec M.   Deporte-Fety R.   Chatelut E.   Leger F.   Longerey B.   Ecochard L.   Douville I.  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 365-373

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel and Epirubicin as First-Line Treatment for Patients with Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

By Hainsworth John   Yardley Denise   Spigel David   Meluch Anthony   Rinaldi David   Schnell Frederick   Greco F.  

Cancer Investigation, Vol. 24, Iss. 5, 2006-06 ,pp. : 469-473

Informa Healthcare

Access to resources Recommend Favorite

Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: A retrospective cohort analysis

By Nelli Fabrizio   Natoli Guido   Moscetti Luca   Massari Annalisa   D’Auria Giuliana   Fabbri Maria A   Frittelli Patrizia   Ruggeri Enzo M  

Journal of Chemotherapy, Vol. 25, Iss. 2, 2013-04 ,pp. : 112-118

Maney Publishing

Access to resources Recommend Favorite